← Back to home

MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS

Clinical trials for MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS explained in plain language.

Never miss a new study

Get alerted when new MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS trials appear

Sign up with your email to follow new studies for MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

First-in-Human trial tests novel oral drug targeting Cancer's weak spot

Disease control Ongoing

This early-stage study is testing a new oral drug called HRO761 for the first time in people. It aims to find safe doses and see if HRO761, either alone or combined with other cancer drugs, can help control advanced cancers that have specific genetic features called MSI-high or d…

Matched conditions: MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS

Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Apr 04, 2026 05:21 UTC

MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS

Get alerted when new MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS trials appear

First-in-Human trial tests novel oral drug targeting Cancer's weak spot